4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Roivant Sciences Ltd. (ROIV) operates in the Biotechnology industry and is headquartered in London, United Kingdom with about 721 employees. Its market capitalization is roughly $26 billion. In the fiscal year ended 2026-03-31, ROIV reported $8M in revenue and ($300M) in net income.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Interactive charts & full statements → Open the ROIV valuation workbench →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $8M | $29M | $33M | $32M | — |
| Gross Profit | $7M | $28M | $31M | $28M | — |
| Operating Income (EBIT) | ($1.3B) | ($1.1B) | ($825M) | ($809M) | — |
| Net Income | ($300M) | ($172M) | $4.3B | ($1.0B) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $2M | $2M | $2M | $2M | $8M | — |
| Gross Profit | $2M | $1M | $2M | $2M | $7M | — |
| Operating Income (EBIT) | ($355M) | ($339M) | ($306M) | ($285M) | ($285M) | — |
| Net Income | $303M | ($266M) | ($114M) | ($223M) | ($206M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $5.7B | $5.4B | $7.2B | $2.4B | — |
| Total Liabilities | $416M | $250M | $774M | $782M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ROIV viewer.
About TickerBase · Data methodology & sources